Trial Profile
Study of the Predictive Value of Airway Obstruction Reversibility on the Effectiveness of Indacaterol (Onbrez® Breezhaler ®) 150 mcg Once Daily in Patients With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2017
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms REVERBREZ
- Sponsors Novartis
- 19 Sep 2012 Planned End Date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 03 May 2012 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.